Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2025-07-10 Capital/Financing Update
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing an exclusive global licensing agreement between Ichnos Glenmark Innovation (IGI) and AbbVie for a pharmaceutical product (ISB 2001). It contains detailed information about the drug, the agreement terms, company backgrounds, and forward-looking statements. There are no financial statements, regulatory filings, or meeting materials. It is not an earnings release, annual report, or any regulatory filing. The content is a corporate announcement about a licensing deal, which fits best under Capital/Financing Update (CAP) as it relates to a significant business transaction involving licensing and milestone payments.
2025-07-10 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding a newspaper advertisement about a Postal Ballot Notice and e-Voting information, pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It mentions the advertisement publication and availability on the company's website. The document is short (1935 characters) and serves as an announcement or notification rather than a full report or detailed filing. It does not contain financial data, management discussion, or voting results, but rather informs about the publication of a notice. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit other specific categories.
2025-07-02 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding an intimation under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It provides details of Key Managerial Personnel (KMP) authorized for disclosures under Regulation 30. The content is about disclosure of management personnel details for compliance purposes, not a financial report, earnings release, or any other report type. The document is short (2241 characters) and is an official regulatory announcement. It fits best under Regulatory Filings (RNS) as it is a compliance disclosure that does not fit other specific categories.
2025-07-01 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of a postal ballot sent to shareholders of Glenmark Pharmaceuticals Limited. It includes information about the resolution to appoint a new Whole-time Director and Executive Director and Global Chief Financial Officer, the voting process, cut-off dates, and regulatory references such as SEBI Listing Regulations and the Companies Act, 2013. The document is not a report of voting results but the notice and explanatory statement for the postal ballot itself. It is a formal communication to shareholders to seek approval via electronic voting. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or resolutions. The document is lengthy (15,000 characters) and contains substantive details about the resolution and voting process, not just a brief announcement or a results declaration. Therefore, the appropriate classification is PSI with high confidence.
2025-07-01 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a media release announcing the launch of a new pharmaceutical product, TEVIMBRA®, by Glenmark Pharmaceuticals in India. It includes details about the product, its approval, clinical background, and company information. There are no financial statements, regulatory filings, voting results, or management changes. The document is a corporate announcement about a product launch, not a financial report or regulatory filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2025-06-24 English
Cessation
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges regarding the cessation of an Independent Director, Mr. Rajesh Desai, due to completion of his term. It includes details about the reconstitution of board committees following his departure. The document references compliance with SEBI Listing Regulations and provides an annexure with details about the director's cessation. There are no financial statements, earnings data, or detailed management discussion. The content is focused on board/management changes, specifically the change in the board of directors and committee composition. The document length is under 5,000 characters and is a direct announcement, not a report or presentation. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-06-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.